Hepatitis F MCQs With Answer
This concise, Student-friendly post is tailored for B. Pharm students preparing for pharmacology and therapeutics exams. Although Hepatitis F remains an unconfirmed or hypothetical hepatitis designation in the literature, understanding how to evaluate novel hepatic viruses, diagnostic strategies, pharmacologic management, vaccine development, and safety monitoring is essential. These Hepatitis F MCQs with answer emphasize virology principles, hepatic pharmacokinetics, laboratory interpretation, drug-induced liver injury, antiviral mechanisms, and public-health response—skills crucial for a pharmacist. Clear explanations build competence in clinical decision-making, research appraisal, and patient counseling. Now let’s test your knowledge with 50 MCQs on this topic.
Q1. Which statement best describes the current scientific status of “Hepatitis F”?
- It is a well-characterized RNA virus with licensed vaccines.
- It is a confirmed DNA virus causing chronic hepatitis worldwide.
- It is a hypothetical or unconfirmed hepatitis designation with limited evidence.
- It is synonymous with Hepatitis E genotype 3.
Correct Answer: It is a hypothetical or unconfirmed hepatitis designation with limited evidence.
Q2. When investigating a suspected novel hepatitis agent like Hepatitis F, which initial laboratory approach is most appropriate for identification?
- Empirical treatment with broad-spectrum antivirals without testing.
- Routine bacterial cultures from blood only.
- Unbiased metagenomic next-generation sequencing on patient samples.
- Immediate vaccination with hepatitis A and B vaccines.
Correct Answer: Unbiased metagenomic next-generation sequencing on patient samples.
Q3. Which clinical feature is most typical for acute viral hepatitis presentations considered when assessing a new hepatitis agent?
- Progressive peripheral neuropathy without liver enzyme changes.
- Jaundice, anorexia, nausea, and elevated ALT/AST.
- Isolated hematuria with normal LFTs.
- Chronic cough and pulmonary infiltrates.
Correct Answer: Jaundice, anorexia, nausea, and elevated ALT/AST.
Q4. For a novel hepatitis virus, which specimen type provides the highest yield for viral RNA detection?
- Urine collected 48 hours after symptom onset.
- Serum or plasma collected during acute phase.
- Hair shafts from the scalp.
- Saliva collected one month after recovery.
Correct Answer: Serum or plasma collected during acute phase.
Q5. Which diagnostic method differentiates past infection from current infection for classical hepatitis viruses and would be essential when studying Hepatitis F seroepidemiology?
- Complete blood count only.
- Serology distinguishing IgM vs IgG antibodies.
- Chest X-ray.
- Urinalysis for bilirubin.
Correct Answer: Serology distinguishing IgM vs IgG antibodies.
Q6. Which liver enzyme pattern suggests hepatocellular injury commonly seen in viral hepatitis evaluation?
- Predominant elevation of alkaline phosphatase with normal ALT.
- Marked elevation of ALT and AST relative to alkaline phosphatase.
- Isolated hypoalbuminemia only.
- Elevated creatinine kinase with normal liver enzymes.
Correct Answer: Marked elevation of ALT and AST relative to alkaline phosphatase.
Q7. When researching a putative Hepatitis F, which epidemiologic study design is best to identify risk factors during an outbreak?
- Cross-sectional study conducted years after the outbreak.
- Randomized controlled trial assigning exposure.
- Case-control study comparing exposures of cases and matched controls.
- Ecologic study using country-level aggregated data only.
Correct Answer: Case-control study comparing exposures of cases and matched controls.
Q8. Which biosafety practice is essential when handling clinical samples potentially containing an unknown hepatitis virus?
- Processing samples on an open bench with no PPE if they appear clear.
- Use of appropriate biosafety cabinet, gloves, masks, and sharps precautions.
- Autoclave samples only after manual aliquoting without gloves.
- Freezing samples at -20°C in a shared freezer without labeling.
Correct Answer: Use of appropriate biosafety cabinet, gloves, masks, and sharps precautions.
Q9. Which molecular target is commonly exploited when designing antiviral nucleoside analogues for RNA hepatitis viruses?
- Bacterial cell wall synthesis enzymes.
- Viral RNA-dependent RNA polymerase active site.
- Cytosolic ribosomal 60S subunit.
- Host DNA topoisomerase II.
Correct Answer: Viral RNA-dependent RNA polymerase active site.
Q10. For a pharmacist, why is understanding liver metabolism important when advising on medications in a patient with acute hepatitis symptoms?
- Liver metabolism does not affect drug dosing.
- Impaired hepatic metabolism can increase drug levels and toxicity.
- Hepatitis only affects vitamin absorption, not drug clearance.
- Renal excretion always compensates for liver dysfunction.
Correct Answer: Impaired hepatic metabolism can increase drug levels and toxicity.
Q11. Which monitoring parameter is crucial when a patient with viral hepatitis is started on a potentially hepatotoxic drug?
- Regular measurement of serum ALT, AST, and bilirubin levels.
- Weekly hemoglobin electrophoresis.
- Daily ECG monitoring regardless of drug class.
- Monthly pulmonary function tests.
Correct Answer: Regular measurement of serum ALT, AST, and bilirubin levels.
Q12. Which antiviral strategy would be least likely useful against an unknown hepatitis virus until its replication mechanism is known?
- Targeted polymerase inhibitors designed after sequencing.
- Broad-spectrum interferon-based immunotherapy in controlled trials.
- Empiric broad-spectrum antibiotics.
- Monoclonal antibodies developed after antigen identification.
Correct Answer: Empiric broad-spectrum antibiotics.
Q13. Which pharmacokinetic change commonly occurs in patients with severe hepatic dysfunction?
- Increased first-pass metabolism leading to lower oral bioavailability.
- Reduced hepatic clearance leading to prolonged half-life of hepatically cleared drugs.
- Complete compensation by enhanced renal clearance for all drugs.
- No change in protein binding for highly protein-bound drugs.
Correct Answer: Reduced hepatic clearance leading to prolonged half-life of hepatically cleared drugs.
Q14. Which vaccine development phase focuses primarily on safety and immunogenicity in a small group of healthy volunteers?
- Phase IV post-marketing surveillance.
- Phase I clinical trials.
- Phase III large-scale efficacy trials.
- Preclinical animal testing only.
Correct Answer: Phase I clinical trials.
Q15. Which serologic finding would suggest recent acute infection if a specific IgM assay is available for a new hepatitis virus?
- Presence of specific IgG only.
- Presence of specific IgM antibodies.
- Low albumin with no antibodies detected.
- Elevated creatinine with negative antibodies.
Correct Answer: Presence of specific IgM antibodies.
Q16. Which histopathologic feature is commonly seen in viral hepatitis and would be examined in liver biopsy when characterizing a new hepatitis?
- Portal and lobular lymphocytic infiltration with hepatocyte necrosis.
- Glomerular crescents with no liver inflammation.
- Interstitial lung fibrosis pattern in liver tissue.
- Normal hepatic architecture with fat only.
Correct Answer: Portal and lobular lymphocytic infiltration with hepatocyte necrosis.
Q17. Which statement about chronicity risk is appropriate when assessing an uncharacterized hepatitis agent?
- All novel hepatitis agents invariably cause chronic infection in 90% of cases.
- Chronicity risk depends on viral properties, host immunity, and age at infection.
- Chronic infection can be diagnosed based on a single transient ALT elevation.
- Chronicity is irrelevant for public health planning.
Correct Answer: Chronicity risk depends on viral properties, host immunity, and age at infection.
Q18. Which public-health measure is most important during an outbreak of an unknown hepatitis-like illness?
- Immediate cessation of all food imports without investigation.
- Rapid case identification, contact tracing, and source investigation.
- Removing all vaccines from clinics.
- Quarantine of all asymptomatic healthcare workers indefinitely.
Correct Answer: Rapid case identification, contact tracing, and source investigation.
Q19. Which laboratory technique would allow confirmation that a detected viral sequence is associated with disease rather than a harmless commensal?
- Detection of identical viral sequence in unrelated environmental samples only.
- Demonstration of higher viral loads in symptomatic cases versus controls and temporal association with illness.
- Reliance solely on seroprevalence without clinical correlation.
- Measuring glucose levels in patients.
Correct Answer: Demonstration of higher viral loads in symptomatic cases versus controls and temporal association with illness.
Q20. Which statement about cross-reactivity is important when developing serologic tests for a novel hepatitis agent?
- Cross-reactivity is desirable because it increases sensitivity for any virus.
- Cross-reactivity may cause false positives if antibodies against known hepatitis viruses bind to the new antigen.
- Cross-reactivity only occurs with bacterial antigens, not viral.
- Cross-reactivity eliminates the need for confirmatory molecular tests.
Correct Answer: Cross-reactivity may cause false positives if antibodies against known hepatitis viruses bind to the new antigen.
Q21. Which antiviral mechanism reduces viral infectivity by preventing virion entry into hepatocytes?
- Nucleoside analogues that inhibit polymerase inside the cell.
- Protease inhibitors that block viral polyprotein processing only after replication.
- Entry inhibitors or neutralizing monoclonal antibodies targeting viral surface proteins.
- Antibiotics that inhibit bacterial cell wall.
Correct Answer: Entry inhibitors or neutralizing monoclonal antibodies targeting viral surface proteins.
Q22. When counseling patients about hepatitis symptoms, which point is most appropriate for a community pharmacist?
- Ignore jaundice; it always resolves without evaluation.
- Advise urgent medical evaluation if jaundice, dark urine, or severe abdominal pain occurs.
- Recommend stopping all prescription medications immediately without consulting a physician.
- Suggest herbal detox regimens as first-line therapy.
Correct Answer: Advise urgent medical evaluation if jaundice, dark urine, or severe abdominal pain occurs.
Q23. Which antivirals approved for other hepatitis viruses might provide a starting point for repurposing against a novel hepatitis if the replication enzyme is similar?
- Nucleos(t)ide analogues targeting viral polymerases.
- Broad-spectrum antifungals like fluconazole.
- Topical antivirals used for skin warts only.
- Antiparasitic agents with no antiviral activity.
Correct Answer: Nucleos(t)ide analogues targeting viral polymerases.
Q24. Which adverse effect of interferon therapy is important for pharmacists to monitor?
- Hypertension without other symptoms.
- Neuropsychiatric symptoms including depression and cytopenias.
- Immediate renal failure in all patients.
- Painless hyperpigmentation only.
Correct Answer: Neuropsychiatric symptoms including depression and cytopenias.
Q25. Which is the best laboratory marker to assess hepatic synthetic function relevant to drug dosing?
- Prothrombin time/INR and serum albumin.
- Blood glucose alone.
- Urine specific gravity.
- Serum amylase only.
Correct Answer: Prothrombin time/INR and serum albumin.
Q26. Which statement about drug-induced liver injury (DILI) is correct?
- DILI only occurs after decades of therapy.
- DILI may present with hepatocellular, cholestatic, or mixed patterns and can mimic viral hepatitis.
- DILI is easily distinguished from viral hepatitis by a single blood test.
- All herbal products are safe and never cause DILI.
Correct Answer: DILI may present with hepatocellular, cholestatic, or mixed patterns and can mimic viral hepatitis.
Q27. Which pharmacologic principle is important when dosing a drug that is extensively metabolized by CYP3A4 in a patient with hepatic impairment?
- No dose adjustment is ever needed for hepatic impairment.
- Consider dose reduction or alternative agents due to reduced metabolic capacity and potential drug interactions.
- CYP3A4 activity always increases in liver disease, so increase dose.
- Hepatic impairment affects only renal drug elimination.
Correct Answer: Consider dose reduction or alternative agents due to reduced metabolic capacity and potential drug interactions.
Q28. Which surveillance measure helps estimate population exposure to a novel hepatitis agent?
- Wastewater surveillance and seroprevalence studies.
- Only hospital billing data without clinical correlation.
- Counting the number of pharmacists in a city.
- Monitoring sales of antacids exclusively.
Correct Answer: Wastewater surveillance and seroprevalence studies.
Q29. Which ethical consideration is paramount when conducting research on patients with suspected Hepatitis F?
- Conduct studies without consent to speed up results.
- Ensure informed consent, confidentiality, and risk minimization in vulnerable populations.
- Exclude reporting of serious adverse events to avoid alarm.
- Prioritize publication speed over participant safety.
Correct Answer: Ensure informed consent, confidentiality, and risk minimization in vulnerable populations.
Q30. Which pharmacovigilance action should a pharmacist take when a patient reports suspected hepatotoxicity after starting a new drug?
- Ignore the report if the drug is over-the-counter.
- Report the adverse event to the national pharmacovigilance center and advise medical evaluation.
- Advise the patient to continue the drug without consultation.
- Notify social media without de-identifying patient data.
Correct Answer: Report the adverse event to the national pharmacovigilance center and advise medical evaluation.
Q31. Which feature distinguishes fulminant hepatic failure from uncomplicated acute hepatitis?
- Rapid development of hepatic encephalopathy and coagulopathy within weeks.
- Only mild nausea with normal INR.
- Isolated chronic fatigue for years without lab abnormalities.
- Presence of cough and sputum production only.
Correct Answer: Rapid development of hepatic encephalopathy and coagulopathy within weeks.
Q32. Which quality control measure is critical for molecular assays developed for a novel hepatitis agent?
- No need for external controls if internal control is present.
- Inclusion of positive and negative controls plus external proficiency testing.
- Using undiluted patient samples as standards.
- Relying solely on visual color change without controls.
Correct Answer: Inclusion of positive and negative controls plus external proficiency testing.
Q33. Which factor increases the likelihood that a newly identified viral sequence is a true human pathogen?
- The sequence is found only in healthy controls and never in cases.
- Experimental infection in an appropriate animal model produces similar disease features.
- The virus cannot be detected by any method.
- The sequence differs from known viruses by a single nucleotide only.
Correct Answer: Experimental infection in an appropriate animal model produces similar disease features.
Q34. Which counseling point is important for patients receiving hepatically cleared antivirals?
- Always take the medication with grapefruit juice to enhance absorption.
- Inform about potential drug interactions, avoid alcohol, and report side effects promptly.
- Stop all other medications without consulting a clinician.
- Double the dose if symptoms persist after one day.
Correct Answer: Inform about potential drug interactions, avoid alcohol, and report side effects promptly.
Q35. Which marker is more specific for cholestatic liver injury than hepatocellular injury?
- ALT predominance over alkaline phosphatase.
- Marked elevation of alkaline phosphatase and gamma-glutamyl transferase.
- Isolated high creatine kinase.
- Low hemoglobin alone.
Correct Answer: Marked elevation of alkaline phosphatase and gamma-glutamyl transferase.
Q36. Which laboratory pattern often indicates alcoholic liver disease rather than viral hepatitis?
- AST:ALT ratio greater than 2 with moderate elevations.
- ALT dramatically higher than AST by 10-fold.
- Isolated elevated bilirubin with normal transaminases.
- Markedly elevated alkaline phosphatase only.
Correct Answer: AST:ALT ratio greater than 2 with moderate elevations.
Q37. Which is the main reason to perform genetic sequencing of a novel hepatitis virus genome?
- To immediately approve a drug without trials.
- To characterize viral taxonomy, identify drug targets, and design diagnostics.
- Sequencing has no role in infectious disease investigations.
- To replace all serologic testing permanently.
Correct Answer: To characterize viral taxonomy, identify drug targets, and design diagnostics.
Q38. Which clinical sign suggests portal hypertension secondary to chronic liver disease rather than acute viral hepatitis?
- Splenomegaly, ascites, and variceal bleeding.
- Transient mild fever only.
- Acute cough and sore throat.
- Isolated muscle spasm.
Correct Answer: Splenomegaly, ascites, and variceal bleeding.
Q39. Which factor would most strongly argue against a novel virus as the cause of an outbreak?
- Consistent exposure history among cases and detection of a new virus in cases.
- Absence of any plausible pathogen in cases despite exhaustive testing and identification of a chemical toxin instead.
- Temporal clustering of cases around a single event.
- Reproducible detection of the same viral sequence in multiple cases.
Correct Answer: Absence of any plausible pathogen in cases despite exhaustive testing and identification of a chemical toxin instead.
Q40. Which pharmacologic class includes drugs that may require dose reduction in severe hepatic impairment due to high hepatic extraction ratio?
- Drugs primarily excreted unchanged in urine only.
- High-extraction drugs with significant first-pass metabolism.
- Drugs with zero hepatic metabolism and no protein binding.
- Inhaled anesthetics exclusively.
Correct Answer: High-extraction drugs with significant first-pass metabolism.
Q41. Which approach helps differentiate acute viral hepatitis from exacerbation of chronic hepatitis?
- Single elevated ALT without history is diagnostic of chronic exacerbation.
- Assess serial liver enzymes, prior serology, and clinical history for baseline chronic markers.
- Rely only on patient-reported fatigue duration.
- Assume chronic disease if the patient is over 30 years old.
Correct Answer: Assess serial liver enzymes, prior serology, and clinical history for baseline chronic markers.
Q42. Which regulatory requirement is essential before initiating clinical trials of a candidate vaccine against a novel hepatitis agent?
- No preclinical data are needed if there is an urgent outbreak.
- Comprehensive preclinical safety and immunogenicity data in relevant models and regulatory approvals.
- Only marketing authorization is required, skipping trials.
- Human trials can start based on theoretical models alone.
Correct Answer: Comprehensive preclinical safety and immunogenicity data in relevant models and regulatory approvals.
Q43. Which biochemical ratio is commonly elevated in viral hepatitis with hepatocellular injury?
- Albumin:globulin ratio always above normal.
- ALT:AST ratio greater than 2 in viral hepatitis.
- ALT often higher than AST (ALT>AST) in many acute viral hepatitis cases.
- Cholesterol:triglyceride ratio diagnostic of viral hepatitis.
Correct Answer: ALT often higher than AST (ALT>AST) in many acute viral hepatitis cases.
Q44. Which approach reduces the risk of transfusion-associated transmission when the causative agent is unknown?
- Stop all blood donations permanently.
- Implement donor screening questionnaires, quarantine of blood, and pathogen-reduction technologies when possible.
- Use only whole blood without testing.
- Assume all donors are infected and discard all blood routinely.
Correct Answer: Implement donor screening questionnaires, quarantine of blood, and pathogen-reduction technologies when possible.
Q45. Which statement about zoonotic origin investigation is relevant for a novel hepatitis agent?
- Zoonotic sources are never responsible for human hepatitis viruses.
- Investigating animal reservoirs and human–animal interfaces can identify spillover risks.
- Only plant viruses are considered in hepatitis outbreaks.
- Zoonotic investigations should be avoided due to ethical concerns.
Correct Answer: Investigating animal reservoirs and human–animal interfaces can identify spillover risks.
Q46. Which drug interaction concern is most relevant with hepatically metabolized antivirals?
- Concomitant use of strong CYP inducers may reduce antiviral concentrations and efficacy.
- CYP inducers only affect renal clearance, not antivirals.
- All herbals enhance antiviral activity safely.
- Drug interactions are negligible for all antivirals.
Correct Answer: Concomitant use of strong CYP inducers may reduce antiviral concentrations and efficacy.
Q47. Which sample handling practice preserves RNA integrity for downstream sequencing of a suspected RNA hepatitis virus?
- Storing serum at room temperature for several days before processing.
- Immediate cold-chain preservation (4°C short-term or −80°C long-term) with RNA stabilizers if available.
- Repeated freeze-thaw cycles to enhance detection.
- Exposing samples to sunlight to inactivate bacteria.
Correct Answer: Immediate cold-chain preservation (4°C short-term or −80°C long-term) with RNA stabilizers if available.
Q48. Which patient population is typically prioritized for passive immunoprophylaxis if exposed to a newly characterized hepatitis virus and a specific immunoglobulin is available?
- Healthy adults with no comorbidities only.
- High-risk groups such as neonates, immunocompromised persons, and post-exposure individuals.
- Only individuals with resolved infection from any hepatitis virus.
- Everyone regardless of exposure or risk, indefinitely.
Correct Answer: High-risk groups such as neonates, immunocompromised persons, and post-exposure individuals.
Q49. Which outcome measure is most important in phase III vaccine efficacy trials for a hepatitis virus?
- Reduction in laboratory-confirmed symptomatic infection compared to placebo or control.
- Change in participants’ hair color after vaccination.
- Increase in local pharmacy sales of unrelated medications.
- Immediate elimination of all liver disease worldwide.
Correct Answer: Reduction in laboratory-confirmed symptomatic infection compared to placebo or control.
Q50. Which interdisciplinary collaboration is key when characterizing and responding to an emerging hepatitis agent like Hepatitis F?
- Only pharmacists working in isolation.
- Collaboration among clinicians, virologists, epidemiologists, public-health officials, and pharmacists.
- Only veterinary services without human health input.
- Marketing teams focusing solely on product branding.
Correct Answer: Collaboration among clinicians, virologists, epidemiologists, public-health officials, and pharmacists.
